P-selectin and subclinical and clinical atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA)

Atherosclerosis

Volumn 240, Issue 1, 2015, Pages 3-9

  Bielinski, Suzette J ^a   Berardi, Cecilia ^a,b   Decker, Paul A ^a   Kirsch, Phillip S ^a,h   Larson, Nicholas B ^a   Pankow, James S ^c   Sale, Michele ^d   de Andrade, Mariza ^a   Sicotte, Hugues ^a   Tang, Weihong ^c   Hanson, Naomi Q ^e   Wassel, Christina L ^f   Polak, Joseph F ^g   Tsai, Michael Y ^e  

^a MAYO CLINIC   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNITEDHEALTH GROUP   (United States)

Author keywords

Atherosclerosis; Cardiovascular risk factors; Coronary artery calcium; P selectin

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER; SELP PROTEIN, HUMAN;

ADULT; AFRICAN; AFRICAN AMERICAN; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ASIAN AMERICAN; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHINESE; CORONARY ARTERY; DIABETES MELLITUS; ETHNIC GROUP; EUROPEAN AMERICAN; FEMALE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SMOKING; ASYMPTOMATIC DISEASE; BLOOD; CAROTID ARTERY DISEASES; CAUCASIAN; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; EPIDEMIOLOGY; ETHNOLOGY; INCIDENCE; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SEX DIFFERENCE; STATISTICAL MODEL; UNITED STATES; VASCULAR CALCIFICATION; VERY ELDERLY;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ASIAN AMERICANS; ASYMPTOMATIC DISEASES; BIOMARKERS; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MALE; MIDDLE AGED; P-SELECTIN; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEX FACTORS; UNITED STATES; VASCULAR CALCIFICATION;

EID: 84923853337     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.02.036     Document Type: Article

References (47)

1. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Blaha M.J., Dai S., Ford E.S., Fox C.S., Franco S., Fullerton H.J., Gillespie C., Hailpern S.M., Heit J.A., Howard V.J., Huffman M.D., Judd S.E., Kissela B.M., Kittner S.J., Lackland D.T., Lichtman J.H., Lisabeth L.D., Mackey R.H., Magid D.J., Marcus G.M., Marelli A., Matchar D.B., McGuire D.K., Mohler E.R., Moy C.S., Mussolino M.E., Neumar R.W., Nichol G., Pandey D.K., Paynter N.P., Reeves M.J., Sorlie P.D., Stein J., Towfighi A., Turan T.N., Virani S.S., Wong N.D., Woo D., Turner M.B. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014, 129:e28-e292.
2. Stenberg P.E., McEver R.P., Shuman M.A., Jacques Y.V., Bainton D.F. Aplateletalpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J.Cell. Biol. 1985, 101:880-886.
3. Bonfanti R., Furie B.C., Furie B., Wagner D.D. PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood 1989, 73:1109-1112.
4. McEver R.P., Beckstead J.H., Moore K.L., Marshall-Carlson L., Bainton D.F. GMP-140, a plateletalpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J.Clin. Invest 1989, 84:92-99.
5. Andre P., Hartwell D., Hrachovinova I., Saffaripour S., Wagner D.D. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc. Natl. Acad. Sci. USA 2000, 97:13835-13840.
6. Hamburger S.A., McEver R.P. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood 1990, 75:550-554.
7. Harrison P., Cramer E.M. Plateletalpha-granules. Blood Rev. 1993, 7:52-62.
8. Fijnheer R., Frijns C.J., Korteweg J., Rommes H., Peters J.H., Sixma J.J., Nieuwenhuis H.K. The origin of P-selectin as a circulating plasma protein. Thromb. Haemost. 1997, 77:1081-1085.
9. Kisucka J., Chauhan A.K., Zhao B.Q., Patten I.S., Yesilaltay A., Krieger M., Wagner D.D. Elevated levels of soluble P-selectin in mice alter blood-brain barrier function, exacerbate stroke, and promote atherosclerosis. Blood 2009, 113:6015-6022.
10. An G., Wang H., Tang R., Yago T., McDaniel J.M., McGee S., Huo Y., Xia L. P-selectin glycoprotein ligand-1 is highly expressed on Ly-6Chi monocytes and a major determinant for Ly-6Chi monocyte recruitment to sites of atherosclerosis in mice. Circulation 2008, 117:3227-3237.
11. Gitlin J.M., Homeister J.W., Bulgrien J., Counselman J., Curtiss L.K., Lowe J.B., Boisvert W.A. Disruption of tissue-specific fucosyltransferase VII, an enzyme necessary for selectin ligand synthesis, suppresses atherosclerosis in mice. Am. J. Pathol. 2009, 174:343-350.
12. Ridker P.M., Buring J.E., Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001, 103:491-495.
13. Varughese G.I., Patel J.V., Tomson J., Blann A.D., Hughes E.A., Lip G.Y. Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial. J.Intern Med. 2007, 261:384-391.
14. Snoep J.D., Roest M., Barendrecht A.D., De Groot P.G., Rosendaal F.R., Van Der Bom J.G. High platelet reactivity is associated with myocardial infarction in premenopausal women: a population-based case-control study. J.Thromb. Homeost. 2010, 8:906-913.
15. Lee D.S., Larson M.G., Lunetta K.L., Dupuis J., Rong J., Keaney J.F., Lipinska I., Baldwin C.T., Vasan R.S., Benjamin E.J. Clinical and genetic correlates of soluble P-selectin in the community. J.Thromb. Haemost. 2008, 6:20-31.
16. Reiner A.P., Carlson C.S., Thyagarajan B., Rieder M.J., Polak J.F., Siscovick D.S., Nickerson D.A., Jacobs D.R., Gross M.D. Soluble P-selectin, SELP polymorphisms, and atherosclerotic risk in European-American and African-African young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1549-1555.
17. Demerath E., Towne B., Blangero J., Siervogel R.M. The relationship of soluble ICAM-1, VCAM-1, P-selectin and E-selectin to cardiovascular disease risk factors in healthy men and women. Ann. Hum. Biol. 2001, 28:664-678.
18. Bild D.E., Bluemke D.A., Burke G.L., Detrano R., Diez Roux A.V., Folsom A.R., Greenland P., Jacob D.R., Kronmal R., Liu K., Nelson J.C., O'Leary D., Saad M.F., Shea S., Szklo M., Tracy R.P. Multi-ethnic study of atherosclerosis: objectives and design. Am. J. Epidemiol. 2002, 156:871-881.
19. Carr J.J., Nelson J.C., Wong N.D., McNitt-Gray M., Arad Y., Jacobs D.R., Sidney S., Bild D.E., Williams O.D., Detrano R.C. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology 2005, 234:35-43.
20. Polak J.F., Pencina M.J., O'Leary D.H., D'Agostino R.B. Common carotid artery intima-media thickness progression as a predictor of stroke in multi-ethnic study of atherosclerosis. Stroke 2011, 42:3017-3021.
21. Yeboah J., Folsom A.R., Burke G.L., Johnson C., Polak J.F., Post W., Lima J.A., Crouse J.R., Herrington D.M. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 2009, 120:502-509.
22. White A.D., Folsom A.R., Chambless L.E., Sharret A.R., Yang K., Conwill D., Higgins M., Williams O.D., Tyroler H.A. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. J.Clin. Epidemiol. 1996, 49:223-233.
23. Fornage M., Boerwinkle E., Doris P.A., Jacobs D., Liu K., Wong N.D. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 2004, 109:335-339.
24. Tobin J. Estimation for relationships with limited dependent variables. Econometrica 1958, 26:24-36.
25. Blann A.D., Faragher E.B., McCollum C.N. Increased soluble P-selectin following myocardial infarction: a new marker for the progression of atherosclerosis. Blood Coagul. Fibrinolysis 1997, 8:383-390.
26. Kvasnicka T., Kvasnicka J., Ceska R., Vrablik M. Increase of inflammatory state in overweight adults with combined hyperlipidemia. Nutr. Metab. Cardiovasc Dis. 2003, 13:227-231.
27. Blann A.D., Goode G.K., Miller J.P., McCollum C.N. Soluble P-selectin in hyperlipidaemia with and without symptomatic vascular disease: relationship with von Willebrand factor. Blood Coagul. Fibrinolysis 1997, 8:200-204.
28. Davi G., Romano M., Mezzetti A., Procopio A., Iacobelli S., Antidormi T., Bucciarelli T., Alessandrini P., Cuccurullo F., Bittolo Bon G. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 1998, 97:953-957.
29. Cipollone F., Mezzetti A., Porreca E., Di Febbo C., Nutini M., Fazia M., Falco A., Cuccurullo F., Davi G. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002, 106:399-402.
30. Theilmeier G., Michiels C., Spaepen E., Vreys I., Collen D., Vermylen J., Hoylaerts M.F. Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood 2002, 99:4486-4493.
31. Romano M., Mezzetti A., Marulli C., Ciabattoni G., Febo F., Di Ienno S., Roccaforte S., Vigneri S., Nubile G., Milani M., Davi G. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J.Investig. Med. 2000, 48:183-189.
32. Bickel C., Rupprecht H.J., Blankenberg S., Espinola-Klein C., Rippin G., Hafner G., Lotz J., Prellwitz W., Meyer J. Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int. J. Cardiol. 2002, 82:25-31.
33. Berkan O., Katrancioglu N., Ozker E., Ozerdem G., Bakici Z., Yilmaz M.B. Reduced P-selectin in hearts pretreated with fluvastatin: a novel benefit for patients undergoing open heart surgery. Thorac. Cardiovasc Surg. 2009, 57:91-95.
34. Kirk G., McLaren M., Muir A.H., Stonebridge P.A., Belch J.J. Decrease in P-selectin levels in patients with hypercholesterolaemia and peripheral arterial occlusive disease after lipid-lowering treatment. Vasc. Med. 1999, 4:23-26.
35. Lee W.J., Lee W.L., Tang Y.J., Liang K.W., Chien Y.H., Tsou S.S., Sheu W.H. Early improvements in insulin sensitivity and inflammatory markers are induced by pravastatin in nondiabetic subjects with hypercholesterolemia. Clin. Chim. Acta 2008, 390:49-55.
36. Marschang P., Friedrich G.J., Ditlbacher H., Stoeger A., Nedden D.Z., Kirchmair R., Dienstl A., Pachinger O., Patsch J.R. Reduction of soluble P-selectin by statins is inversely correlated with the progression of coronary artery disease. Int. J. Cardiol. 2006, 106:183-190.
37. Oka H., Ikeda S., Koga S., Miyahara Y., Kohno S. Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases. Heart Vessels 2008, 23:249-256.
38. Nadar S.K., Blann A.D., Lip G.Y. Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: effects of antihypertensive therapy. J.Intern Med. 2004, 256:331-337.
39. Spencer C.G., Gurney D., Blann A.D., Beevers D.G., Lip G.Y. Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension 2002, 40:61-66.
40. Lip G.Y., Blann A.D., Zarifis J., Beevers M., Lip P.L., Beevers D.G. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: implications for atherogenesis? A preliminary report. J.Hypertens. 1995, 13:1674-1678.
41. Preston R.A., Coffey J.O., Materson B.J., Ledford M., Alonso A.B. Elevated platelet P-selectin expression and platelet activation in high risk patients with uncontrolled severe hypertension. Atherosclerosis 2007, 192:148-154.
42. Nomura S., Inami N., Shouzu A., Urase F., Maeda Y. Correlation and association between plasma platelet-, monocyte- and endothelial cell-derived microparticles in hypertensive patients with type 2 diabetes mellitus. Platelets 2009, 20:406-414.
43. Shalia K.K., Mashru M.R., Vasvani J.B., Mokal R.A., Mithbawkar S.M., Thakur P.K. Circulating levels of cell adhesion molecules in hypertension. Indian J. Clin. Biochem. 2009, 24:388-397.
44. Butkiewicz A.M., Kemona-Chetnik I., Dymicka-Piekarska V., Matowicka-Karna J., Kemona H., Radziwon P. Does smoking affect thrombocytopoiesis and platelet activation in women and men?. Adv. Med. Sci. 2006, 51:123-126.
45. Ay C., Dunkler D., Marosi C., Chiriac A.L., Vormittag R., Simanek R., Quehenberger P., Zielinski C., Pabinger I. Prediction of venous thromboembolism in cancer patients. Blood 2010, 116:5377-5382.
46. Blann A.D. Soluble P-selectin: the next step. Thromb. Res. 2014, 133:3-4.
47. Antonopoulos C.N., Sfyroeras G.S., Kakisis J.D., Moulakakis K.G., Liapis C.D. The role of soluble P selectin in the diagnosis of venous thromboembolism. Thromb. Res. 2014, 133:17-24.